Ascelia Pharma Provides Orviglance Update

Ascelia Pharma AB (publ) (STO:ACE), a biopharmaceutical company focused on improving the lives of people living with rare cancer conditions, provides an update following the recent publication of the Complete Response Letter (CRL) by the U.S. Food …